Iterum (ITRM) says FDA needs more time to review materials in support of NDA for sulopenem etzadroxil/probenecid
Go back to Iterum (ITRM) says FDA needs more time to review materials in support of NDA for sulopenem etzadroxil/probenecid| Intermountain Ventures, Inc. (NASDAQ: ITRM) | Delayed: 1.57 +0.02 (1.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.55 | 52 Week High | $0.15 | |||
| Open | $1.52 | 52 Week Low | $0.00 | |||
| Day High | $1.57 | P/E | N/A | |||
| Day Low | $1.50 | EPS | $0.00 | |||
| Volume | 50,986 | |||||
